Serveur d'exploration sur la COVID chez les séniors

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Anaphylactic shock following the diagnosis of coronavirus disease 2019.

Identifieur interne : 000940 ( Main/Exploration ); précédent : 000939; suivant : 000941

Anaphylactic shock following the diagnosis of coronavirus disease 2019.

Auteurs : Alberto Alvarez-Perea [Espagne] ; María Luisa Baeza [Espagne]

Source :

RBID : pubmed:32745608

Descripteurs français

English descriptors


DOI: 10.1016/j.anai.2020.07.032
PubMed: 32745608
PubMed Central: PMC7395240


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Anaphylactic shock following the diagnosis of coronavirus disease 2019.</title>
<author>
<name sortKey="Alvarez Perea, Alberto" sort="Alvarez Perea, Alberto" uniqKey="Alvarez Perea A" first="Alberto" last="Alvarez-Perea">Alberto Alvarez-Perea</name>
<affiliation wicri:level="3">
<nlm:affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain. Electronic address: alberto@alvarezperea.com.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid</wicri:regionArea>
<placeName>
<settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Baeza, Maria Luisa" sort="Baeza, Maria Luisa" uniqKey="Baeza M" first="María Luisa" last="Baeza">María Luisa Baeza</name>
<affiliation wicri:level="3">
<nlm:affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid</wicri:regionArea>
<placeName>
<settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32745608</idno>
<idno type="pmid">32745608</idno>
<idno type="doi">10.1016/j.anai.2020.07.032</idno>
<idno type="pmc">PMC7395240</idno>
<idno type="wicri:Area/Main/Corpus">000859</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000859</idno>
<idno type="wicri:Area/Main/Curation">000859</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000859</idno>
<idno type="wicri:Area/Main/Exploration">000859</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Anaphylactic shock following the diagnosis of coronavirus disease 2019.</title>
<author>
<name sortKey="Alvarez Perea, Alberto" sort="Alvarez Perea, Alberto" uniqKey="Alvarez Perea A" first="Alberto" last="Alvarez-Perea">Alberto Alvarez-Perea</name>
<affiliation wicri:level="3">
<nlm:affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain. Electronic address: alberto@alvarezperea.com.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid</wicri:regionArea>
<placeName>
<settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Baeza, Maria Luisa" sort="Baeza, Maria Luisa" uniqKey="Baeza M" first="María Luisa" last="Baeza">María Luisa Baeza</name>
<affiliation wicri:level="3">
<nlm:affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid</wicri:regionArea>
<placeName>
<settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology</title>
<idno type="eISSN">1534-4436</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adrenal Cortex Hormones (therapeutic use)</term>
<term>Aged (MeSH)</term>
<term>Anaphylaxis (diagnosis)</term>
<term>Anaphylaxis (drug therapy)</term>
<term>Anaphylaxis (etiology)</term>
<term>Anaphylaxis (pathology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Asthma (complications)</term>
<term>Asthma (diagnosis)</term>
<term>Asthma (drug therapy)</term>
<term>Asthma (pathology)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (immunology)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Biomarkers (blood)</term>
<term>Cefixime (adverse effects)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (pathology)</term>
<term>Disease Progression (MeSH)</term>
<term>Fatal Outcome (MeSH)</term>
<term>Female (MeSH)</term>
<term>Ferritins (blood)</term>
<term>Fibrin Fibrinogen Degradation Products (metabolism)</term>
<term>Humans (MeSH)</term>
<term>Hypertension (complications)</term>
<term>Hypertension (diagnosis)</term>
<term>Hypertension (drug therapy)</term>
<term>Hypertension (pathology)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (pathology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Anaphylaxie (anatomopathologie)</term>
<term>Anaphylaxie (diagnostic)</term>
<term>Anaphylaxie (traitement médicamenteux)</term>
<term>Anaphylaxie (étiologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Asthme (anatomopathologie)</term>
<term>Asthme (complications)</term>
<term>Asthme (diagnostic)</term>
<term>Asthme (traitement médicamenteux)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (immunologie)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Céfixime (effets indésirables)</term>
<term>Femelle (MeSH)</term>
<term>Ferritines (sang)</term>
<term>Hormones corticosurrénaliennes (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hypertension artérielle (anatomopathologie)</term>
<term>Hypertension artérielle (complications)</term>
<term>Hypertension artérielle (diagnostic)</term>
<term>Hypertension artérielle (traitement médicamenteux)</term>
<term>Infections à coronavirus (anatomopathologie)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Issue fatale (MeSH)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (anatomopathologie)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Produits de dégradation de la fibrine et du fibrinogène (métabolisme)</term>
<term>Sujet âgé (MeSH)</term>
<term>Évolution de la maladie (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Cefixime</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Biomarkers</term>
<term>Ferritins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Fibrin Fibrinogen Degradation Products</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Adrenal Cortex Hormones</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Anaphylaxie</term>
<term>Asthme</term>
<term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Asthma</term>
<term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Anaphylaxis</term>
<term>Asthma</term>
<term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr">
<term>Anaphylaxie</term>
<term>Asthme</term>
<term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Anaphylaxis</term>
<term>Asthma</term>
<term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Asthme</term>
<term>Céfixime</term>
<term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Anaphylaxis</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Produits de dégradation de la fibrine et du fibrinogène</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en">
<term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr">
<term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Anaphylaxis</term>
<term>Asthma</term>
<term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Ferritines</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Anaphylaxie</term>
<term>Asthme</term>
<term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Antiviraux</term>
<term>Hormones corticosurrénaliennes</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr">
<term>Anaphylaxie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Disease Progression</term>
<term>Fatal Outcome</term>
<term>Female</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Femelle</term>
<term>Humains</term>
<term>Issue fatale</term>
<term>Pandémies</term>
<term>Sujet âgé</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">32745608</PMID>
<DateCompleted>
<Year>2020</Year>
<Month>10</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>10</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1534-4436</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>125</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2020</Year>
<Month>10</Month>
</PubDate>
</JournalIssue>
<Title>Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology</Title>
<ISOAbbreviation>Ann Allergy Asthma Immunol</ISOAbbreviation>
</Journal>
<ArticleTitle>Anaphylactic shock following the diagnosis of coronavirus disease 2019.</ArticleTitle>
<Pagination>
<MedlinePgn>477-478</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1081-1206(20)30521-4</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.anai.2020.07.032</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Alvarez-Perea</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain. Electronic address: alberto@alvarezperea.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baeza</LastName>
<ForeName>María Luisa</ForeName>
<Initials>ML</Initials>
<AffiliationInfo>
<Affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2020</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Ann Allergy Asthma Immunol</MedlineTA>
<NlmUniqueID>9503580</NlmUniqueID>
<ISSNLinking>1081-1206</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-73-2</RegistryNumber>
<NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>97I1C92E55</RegistryNumber>
<NameOfSubstance UI="D020682">Cefixime</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000707" MajorTopicYN="N">Anaphylaxis</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001249" MajorTopicYN="N">Asthma</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020682" MajorTopicYN="N">Cefixime</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2020</Year>
<Month>06</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2020</Year>
<Month>07</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">32745608</ArticleId>
<ArticleId IdType="pii">S1081-1206(20)30521-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.anai.2020.07.032</ArticleId>
<ArticleId IdType="pmc">PMC7395240</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Ann Allergy Asthma Immunol. 2020 Jun;124(6):550-557</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31881269</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Dermatol. 2020 Jul;183(1):71-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32348545</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World Allergy Organ J. 2014 May 30;7(1):9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24920969</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2386-2387</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32387383</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Allergy Clin Immunol. 2020 Apr;145(4):1082-1123</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32001253</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Immunol. 2017 Jul 26;8:846</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28798744</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Espagne</li>
</country>
<region>
<li>Communauté de Madrid</li>
</region>
<settlement>
<li>Madrid</li>
</settlement>
</list>
<tree>
<country name="Espagne">
<region name="Communauté de Madrid">
<name sortKey="Alvarez Perea, Alberto" sort="Alvarez Perea, Alberto" uniqKey="Alvarez Perea A" first="Alberto" last="Alvarez-Perea">Alberto Alvarez-Perea</name>
</region>
<name sortKey="Baeza, Maria Luisa" sort="Baeza, Maria Luisa" uniqKey="Baeza M" first="María Luisa" last="Baeza">María Luisa Baeza</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000940 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000940 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidSeniorV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32745608
   |texte=   Anaphylactic shock following the diagnosis of coronavirus disease 2019.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32745608" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidSeniorV1 

Wicri

This area was generated with Dilib version V0.6.37.
Data generation: Thu Oct 15 09:49:45 2020. Site generation: Wed Jan 27 17:10:23 2021